Commercialized Products & Marketed Therapies

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.

Canadian specialty pharmaceutical company focused on ketamine-based therapies for psychiatric and neurological conditions. KETARX™ (racemic ketamine IV) received FDA approval in August 2025, making PharmaTher one of the first Canadian companies to achieve US regulatory approval for a ketamine product. Also developing KETABET, a proprietary combination of ketamine and betaine.

The US subsidiary of Teva Pharmaceutical Industries, one of the world's largest pharmaceutical companies. Teva is known globally as a leader in generic medicines and also markets specialty branded drugs for neurological, respiratory, and oncology conditions, with headquarters in Israel and major operations worldwide.

A physician-founded, science-focused medical cannabis company operating cultivations, manufacturing facilities, and dispensaries across multiple US states. Vireo Health integrates medical expertise and pharmaceutical-grade production to provide cannabis-based treatments to patients, with operations in Maryland, Minnesota, and New York and a focus on evidence-based medicine and patient care.

An Australian biotech company developing proprietary synthetic psilocybin formulations and novel psychedelic therapies for mental health disorders. Woke Pharmaceuticals sponsors clinical trials for treatment-resistant depression partnering with leading universities including Swinburne University and the University of Western Australia, and is developing novel LSD analogues through research collaboration aimed at improving therapeutic profiles.